Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP versus TI-CE as first salvage therapy for relapsed or refractory germ cell tumors
2014-003930-17Phase 3Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, ifosfamide, cisplatin, carboplatin and etoposide in germ cell tumor (GCT) and Germ Cell Testicular Cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started May 2015; status: active.
02
Drugs
paclitaxelifosfamidecisplatincarboplatinetoposide
03
Conditions
germ cell tumor (GCT)Germ Cell Testicular Cancer
Beyond the preview
Go deeper on 2014-003930-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003930-17.